DOI: 10.1097/jcp.0000000000001747 ISSN:

Antidepressant-Associated Treatment Emergent Mania

Nicolas A. Nuñez, Brandon J. Coombes, Lindsay Melhuish Beaupre, Francisco Romo-Nava, Manuel Gardea-Resendez, Aysegul Ozerdem, Marin Veldic, Balwinder Singh, Jorge A. Sanchez Ruiz, Alfredo Cuellar-Barboza, Jonathan G. Leung, Miguel L. Prieto, Susan L. McElroy, Joanna M. Biernacka, Mark A. Frye
  • Pharmacology (medical)
  • Psychiatry and Mental health
Show PDF Cite

Abstract

Background

The purpose of this study was to review the association between the SLC6A4 5-HTTLPR polymorphism and antidepressant (AD)-associated treatment emergent mania (TEM) in bipolar disorder alongside starting a discussion on the merits of developing risk stratification models to guide when not to provide AD treatment for bipolar depression.

Methods

Studies that examined the association between clinical and genetic risk factors, specifically monoaminergic transporter genetic variation, and TEM were identified. A meta-analysis was performed using the odds ratio to estimate the effect size under the Der-Simonian and Laird model.

Results

Seven studies, referencing the SLC6A4 5-HTTLPR polymorphism and TEM (total N = 1578; TEM+ =594, TEM− = 984), of 142 identified articles were included. The time duration between the start of the AD to emergence of TEM ranged from 4 to 12 weeks. There was a nominally significant association between the s allele of the 5-HTTLPR polymorphism and TEM (odds ratio, 1.434; 95% confidence interval, 1.001–2.055; P = 0.0493; I 2 = 52%). No studies have investigated norepinephrine or dopamine transporters.

Conclusion

Although the serotonin transporter genetic variation is commercially available in pharmacogenomic decision support tools, greater efforts, more broadly, should focus on complete genome-wide approaches to determine genetic variants that may contribute to TEM. Moreover, these data are exemplary to the merits of developing risk stratification models, which include both clinical and biological risk factors, to guide when not to use ADs in bipolar disorder. Future studies will need to validate new risk models that best inform the development of personalized medicine best practices treating bipolar depression.

More from our Archive